scott_byrd

Acacia Pharma appoints two directors to board

pharmafile | March 6, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acacia pharma, christine soden, scott byrd 

UK pharma firm Acacia Pharma that develops drugs for supportive care has confirmed Scott Byrd and Christine Soden have joined its board of directors.

Byrd (pictured) has 23 years of experience in the pharma industry and was most recently the chief commercial officer of Cadence Pharmaceuticals from June 2009 – until the company’s acquisition by Mallinckrodt in March last year.

Previously he served in a variety of US and global roles in sales, marketing, finance, manufacturing and strategic planning at Eli Lilly since 1992.

Advertisement

Soden is a chartered accountant and is the chief financial officer of the UK-listed medical device company, Electrical Geodesics. Previously she was the CFO of Optos, BTG and Celltech-Chiroscience – following senior finance roles with life sciences companies including Oxagen Limited and Medeva.

Ian Kent, Acacia Pharma’s chairman says: “We are delighted to welcome Scott and Christine to the Board. They bring significant commercial and financial experience to the company’s leadership team at a crucial time in its development.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content